Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 734 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Building a Balanced Breakfast November 6, 2020 Rare Disease Day 2026: Advancing equity for people living with rare... February 27, 2026 Re-Thinking Community December 10, 2021 Mom Gives ‘Elf On The Shelf’ A Wheelchair For Daughter With... December 23, 2021 Load more HOT NEWS How Can Hormone Replacement Therapy for Menopause Impact My Cancer Risk? FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type FDA Approves Elacestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast... EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions...
